Skip to main content
. 2019 Nov 29;9:1343. doi: 10.3389/fonc.2019.01343

Figure 5.

Figure 5

Establishment (A) and validation (B,C) of the cohorts based on real-world and clinical trial data. *Sample size ratio was calculated based on the NPC-specific real-world dataset including 10,126 patients. Baseline of the selected T3–4N0 NPC patients was matched with the trial data using the PSM method. NPC, nasopharyngeal carcinoma; PSM, propensity score matching; TPF, docetaxel–cisplatin−5-fluorouracil; IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; OS, overall survival; HR, hazard ratio; CI, confidence interval; Ref., reference.